The Specimen Core will provide SPORE investigators with well-characterized biologic specimens, including tissues, blood, and tissue derivatives, that are essential for achieving the aims ofthe projects. The Specimen Core has a large repository of paraffin blocks, frozen samples, plasma, serum, and bone marrow that spans the entire spectrum of prostate cancer. The repository includes primary tumors and metastases from therapy-resistant tumors and tumors derived from radical prostatectomy specimens from patients given novel preoperative therapies as part of studies conducted at The University of Texas M. D. Anderson Cancer Center and other, multi-institutional efforts. This material, supplemented in select cases with matching biopsy specimens, plasma, serum, and bone marrow aspirates collected before therapy, will provide SPORE investigators with optimal tissue samples with which to address the proposed basic and translational research tissue requirements of the projects. We have also established biologic models (cell lines and xenografts) relevant to the projects. Tissue requests and approval by the Tissue Acquisition and Distribution Committee will be handled electronically. Tissue derivatives, including tissue microarrays, cRNA, and DNA, will optimize the use of limited samples and enhance collaboration among investigators at M. D. Anderson and other institutions. Structured information derived from standardized, high-throughput assays of differential gene expression, both of protein (immunohistochemistry) and RNA (oligonucleotide arrays and multiplexed PCR), will be available to individual SPORE investigators to facilitate modular and gene network analysis in specific clinical contexts. A unique feature of the Specimen Core will be the ability to link comprehensive clinical and pathologic information to the morphologic and molecular characterization of selected pathways. This linkage will be accomplished, in cooperation with the Biostatistics and Bioinformatics Core, by using a Web-based portal. By using this Web-based system to access and query SPORE data, we will pool laboratory resources, facilitate the translational research proposed in the projects, and accelerate successful achievement of the proposed aims.

Public Health Relevance

^ The Specimen Core will collect, store and distribute tissue and blood samples from patients with prostate cancer. The Core will also create and maintain cell lines and xenografts from samples of prostate cancer tissues. These materials are essential to conduct the projects of this SPORE proposal. The Core will provide technical support and pathologic expertise to the investigators and will link the clinical and pathologic information to the results obtained from the various experiments.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Luo, Yong; Azad, Abul Kalam; Karanika, Styliani et al. (2017) Enzalutamide and CXCR7 inhibitor Combination Treatment Suppresses Cell Growth and Angiogenic Signaling in Castration-Resistant Prostate Cancer Models. Int J Cancer :
Lin, Song-Chang; Lee, Yu-Chen; Yu, Guoyu et al. (2017) Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Dev Cell 41:467-480.e3
Gao, Jianjun; Ward, John F; Pettaway, Curtis A et al. (2017) VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23:551-555
Yu, Kai-Jie; Li, Jeffrey K; Lee, Yu-Chen et al. (2017) Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone. Oncotarget 8:74987-75006
Tu, Huakang; Gu, Jian; Meng, Qing H et al. (2017) Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett 13:1949-1957
Gökce, Mehmet I; Wang, Xuemei; Frost, Jacqueline et al. (2017) Informed decision making before prostate-specific antigen screening: Initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men. Cancer 123:583-591
Karanika, Styliani; Karantanos, Theodoros; Li, Likun et al. (2017) Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep 18:1970-1981
Saha, Achinto; Blando, Jorge; Fernandez, Irina et al. (2016) Linneg Sca-1high CD49fhigh prostate cancer cells derived from the Hi-Myc mouse model are tumor-initiating cells with basal-epithelial characteristics and differentiation potential in vitro and in vivo. Oncotarget 7:25194-207
Fong, Eliza L S; Wan, Xinhai; Yang, Jun et al. (2016) A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials 77:164-72
Subudhi, Sumit K; Aparicio, Ana; Gao, Jianjun et al. (2016) Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113:11919-11924

Showing the most recent 10 out of 198 publications